{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70759"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/survodutide\/","title":{"rendered":"Survodutida"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es Survodutide?<\/h3>\n<p style=\"margin: 0;\"><strong>Survodutida<\/strong> (developmental code BI 456906) is a 29-amino-acid long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. In published Phase 2 studies it produced striking effects in MASH (metabolic-dysfunction-associated steatohepatitis) liver fibrosis alongside obesity body-weight reductions of ~19% over 46 weeks. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2230198-02-2 (survodutide; com\u00fanmente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Co-agonista dual de acci\u00f3n prolongada de los receptores de GLP-1\/glucag\u00f3n (p\u00e9ptido sint\u00e9tico acilado; BI 456906 de Boehringer Ingelheim; codesarrollado con Zealand Pharma)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3,800 Da (con acilaci\u00f3n de \u00e1cido graso; forma de p\u00e9ptido maduro)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estructura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00e9ptido sint\u00e9tico co-agonista de 29 amino\u00e1cidos con sustituciones de Aib dise\u00f1adas para resistencia a DPP-4 y una cadena acilada de \u00e1cido graso unida a un residuo de lisina mediante un enlazador \u03b3-Glu. Sustancialmente m\u00e1s corto que los agonistas duales derivados de la oxintomodulina (mazdutide ~39 aa) manteniendo una actividad equilibrada en los receptores de GLP-1\/glucag\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos. Los p\u00e9ptidos acilados pueden disolverse m\u00e1s lentamente \u2014 permita tiempo adicional de equilibraci\u00f3n.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es Survodutide?<\/h2>\n<p><strong>Survodutida<\/strong> (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1\/glucagon co-agonist studies programme, alongside the parallel programmes that produced <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">mazdutide<\/a> (Innovent Biologics, China) and the older Pegapamodutide \/ Cotadutide compounds. Survodutide is structurally compact \u2014 just 29 amino acids \u2014 substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation. Survodutide has a mature molecular weight of approximately 3,800\u00a0Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing. The current clinical signature of survodutide is the <strong>efecto llamativo en la fibrosis hep\u00e1tica por MASH (esteatohepatitis asociada a disfunci\u00f3n metab\u00f3lica)<\/strong> reportado en el ensayo de Fase 2 \u2014un resultado que lo distingui\u00f3 de otros agonistas duales y triples con efectos similares en el peso corporal. Los datos de obesidad en Fase 2 mostraron reducciones de peso corporal de aproximadamente 19% a 4,8 mg semanales durante 46 semanas, situando a survodutide en el mismo nivel de efecto que tirzepatide y en el l\u00edmite del agonista triple retatrutide. Survodutide se encuentra actualmente en ensayos de Fase 3 para obesidad (dise\u00f1o de ensayo tipo SURMOUNT) y MASH. Survodutide no est\u00e1 <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sibling dual GLP-1\/glucagon co-agonist, see our <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> p\u00e1gina de producto; para el agonista triple que a\u00f1ade GIP, consulte <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a>. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Coagonismo dual de los receptores de GLP-1\/glucag\u00f3n con \u00e9nfasis hep\u00e1tico<\/h2>\n<p>Lo que hace que survodutide sea distintivo mec\u00e1nicamente entre los p\u00e9ptidos metab\u00f3licos agonistas duales es la <strong>proporci\u00f3n de potencia GLP-1-glucag\u00f3n relativamente equilibrada<\/strong> que produce tanto efectos sustanciales en el gasto energ\u00e9tico (el brazo del glucag\u00f3n) como los efectos can\u00f3nicos de saciedad\/gluc\u00e9micos del GLP-1, con un \u00e9nfasis particular en los resultados hep\u00e1ticos:<\/p>\n<ul>\n<li><strong>Activaci\u00f3n del receptor de GLP-1 \u2014 saciedad, secreci\u00f3n de insulina en las c\u00e9lulas \u03b2, vaciado g\u00e1strico<\/strong> \u2014 Survodutide activa el receptor de GLP-1 en las c\u00e9lulas beta pancre\u00e1ticas (secreci\u00f3n de insulina dependiente de glucosa, supresi\u00f3n de glucag\u00f3n en las c\u00e9lulas alfa), neuronas POMC del n\u00facleo arqueado hipotal\u00e1mico (regulaci\u00f3n central del apetito) y aferentes vagales g\u00e1stricos (retraso del vaciado g\u00e1strico). Este brazo se solapa con el mecanismo de semaglutide y el componente GLP-1 de todos los p\u00e9ptidos incretina multiagonistas.<\/li>\n<li><strong>Activaci\u00f3n del receptor de glucag\u00f3n \u2014 movilizaci\u00f3n de l\u00edpidos hep\u00e1ticos, gasto energ\u00e9tico, activaci\u00f3n del tejido adiposo marr\u00f3n<\/strong> \u2014 La caracter\u00edstica definitoria compartida con <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">mazdutide<\/a> y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> is glucagon-receptor agonism. In survodutide studies, this arm produces particularly strong hepatic lipid mobilisation \u2014 hepatocytes are highly enriched for glucagon receptors, and direct glucagon-pathway activation drives fatty-acid oxidation and triglyceride export. The combined effect with the GLP-1 arm&#8217;s indirect liver benefits via reduced insulin resistance produces the distinctive MASH-fibrosis signal observed in Phase 2.<\/li>\n<li><strong>Ingenier\u00eda del equilibrio de receptores y la proporci\u00f3n de potencia dual-agonista<\/strong> \u2014 The pharmacological challenge in dual GLP-1\/glucagon co-agonism is achieving the right relative potency at each receptor. Glucagon agonism alone raises glucose; GLP-1 agonism alone produces strong glucose-lowering. The net effect depends on the in-vivo ratio of receptor occupancy at each site. Survodutide is engineered for a glucagon-favoured balance relative to mazdutide, which contributes to the stronger hepatic effects but requires more careful titration to avoid net glucose effects in early dose-escalation protocols.<\/li>\n<\/ul>\n<p>The fatty-acid acylation at a lysine residue (analogous in concept to semaglutide&#8217;s C18 acyl chain) drives reversible serum-albumin binding that produces the ~6-day plasma half-life and supports once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Survodutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>MASLD\/MASH (enfermedad hep\u00e1tica asociada a disfunci\u00f3n metab\u00f3lica)<\/strong> \u2014 hepatic triglyceride content, ALT\/AST normalisation, fibrosis-stage progression in preclinical models and clinical Phase 2 data; survodutide&#8217;s strongest signal and the basis for its dedicated MASH Phase 3 programme<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 modelos precl\u00ednicos de roedores con obesidad inducida por dieta (DIO), composici\u00f3n corporal (DEXA\/RMN), ensayos de ingesta alimentaria, medici\u00f3n del gasto energ\u00e9tico<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 control gluc\u00e9mico, din\u00e1mica de supresi\u00f3n de glucag\u00f3n, sustitutos de HbA1c; el equilibrio de receptores dise\u00f1ado favorece un descenso neto de la glucosa a pesar del componente de glucag\u00f3n<\/li>\n<li><strong>Energy-expenditure and thermogenesis studies<\/strong> \u2014 gasto energ\u00e9tico en reposo, activaci\u00f3n del tejido adiposo marr\u00f3n, expresi\u00f3n g\u00e9nica termog\u00e9nica; particularmente relevante dado el componente de glucag\u00f3n<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 comparaci\u00f3n directa con el co-agonista dual alternativo GLP-1\/glucag\u00f3n <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> (derivado de la oxintomodulina, 39 aa), el dual GLP-1\/GIP <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a>, y el tri-agonista <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a>; receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 efectos sobre la presi\u00f3n arterial, perfiles lip\u00eddicos; datos de resultados cardiovasculares acumulados de los programas de Fase 2\/3<\/li>\n<li><strong>Farmacolog\u00eda del eje del glucag\u00f3n<\/strong> \u2014 farmacolog\u00eda aislada del receptor de glucag\u00f3n, din\u00e1mica de producci\u00f3n hep\u00e1tica de glucosa, caracterizaci\u00f3n del equilibrio de potencia entre glucag\u00f3n y receptor GLP-1<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 comparativa con agonista simple de GLP-1 (<a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a>) y farmacolog\u00eda combinada del eje de amilina (<a href=\"https:\/\/medsbase.com\/es\/cagrilintide\/\">Cagrilintida<\/a> + Semaglutida CagriSema).<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre el lugar que ocupa survodutida en el panorama de los p\u00e9ptidos metab\u00f3licos multiagonistas, consulte <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> como el coagonista dual hermano de GLP-1\/glucag\u00f3n, <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> como el triagonista que a\u00f1ade GIP, <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> como la alternativa dual que utiliza GIP en lugar de glucag\u00f3n, y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> como el agonista simple de referencia. Explore el completo <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks Survodutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, estudios multicohorte, menor coste por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 2 clinical doses are 0.3\u20134.8\u00a0mg weekly with a 4\u20136 month titration schedule, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Survodutide is a comparatively scarce peptide because of active clinical development and Western-pharmaceutical supply-chain controls, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>Comparativa \u2014 Survodutida vs Mazdutida<\/h2>\n<p>Survodutida y <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> are the two principal dual GLP-1 \/ glucagon co-agonist peptides in current literature. They share receptor pharmacology \u2014 both activate the GLP-1 and glucagon receptors, both lack GIP activity \u2014 but differ in structural origin, length, and engineered receptor-balance ratio. The comparison is one of the cleanest in current dual-agonist pharmacology because the receptor targets are identical and only the molecular implementation differs. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Survodutida<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucag\u00f3n (dual)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucag\u00f3n (dual)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 amino\u00e1cidos (compacto)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 amino\u00e1cidos (derivado de la oxintomodulina)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desarrollador<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Boehringer Ingelheim + Zealand Pharma<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent Biologics (licencia de Eli Lilly)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>C\u00f3digo de desarrollo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BI 456906<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBI362 \/ LY3305677<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Balance de receptores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Predominio de glucag\u00f3n (fuertes efectos hep\u00e1ticos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Predominio de GLP-1 (perfil gluc\u00e9mico m\u00e1s limpio)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 d\u00edas (administraci\u00f3n semanal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal (acilado)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Se\u00f1al cl\u00ednica distintiva<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mejora de la fibrosis hep\u00e1tica por MASH (Fase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Primer agonista dual aprobado (China NMPA)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto sobre el peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~19% (Fase 2, 46 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317% (Fase 3, 48 semanas)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,3\u20134,8 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For MASH\/MASLD liver-disease studies, survodutide is the more frequently cited dual-agonist tool because of its distinctive Phase 2 hepatic-fibrosis signal. For studies interested in the glycaemic axis with minimal glucagon-pathway interference, mazdutide&#8217;s GLP-1-favoured balance is the cleaner choice. The two peptides together represent the principal Western (Boehringer-Zealand) and Eastern (Innovent) approaches to dual GLP-1\/glucagon co-agonist pharmacology \u2014 both are likely to remain in active studies and clinical development through this decade. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> Almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su embalaje original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. El survodutide liofilizado es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.9\u00a0mL delivers a 4.8\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>ajuste<\/strong> sacuda \u2014 y permita 5\u201310 minutos para una disoluci\u00f3n completa (los p\u00e9ptidos acilados se disuelven m\u00e1s lentamente que los p\u00e9ptidos no modificados m\u00e1s peque\u00f1os). Una soluci\u00f3n correctamente reconstituida debe ser clara e incolora, sin part\u00edculas visibles. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y util\u00edcelo dentro de los 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is Survodutide used for in studies?<\/h3>\n<p>Survodutide is used in studies investigating MASLD\/MASH liver disease (its strongest distinctive signal), obesity and body-composition regulation, type 2 diabetes preclinical models, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), the sibling dual GLP-1\/glucagon mazdutide, and triple-agonist retatrutide. The pharmaceutical-grade survodutide sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el Survodutide del Mazdutide?<\/h3>\n<p>Both are dual GLP-1\/glucagon co-agonists with the same receptor targets, but they differ in structural origin and engineered receptor-balance ratio. Survodutide is a compact 29-amino-acid Boehringer-Zealand compound with a glucagon-favoured potency balance that produces particularly strong hepatic effects (the basis for its Phase 2 MASH signal). Mazdutide is a ~39-amino-acid oxyntomodulin-derived Innovent compound with a GLP-1-favoured balance that produces cleaner glycaemic effects. For MASH studies, survodutide is the canonical choice; for clean glycaemic-axis studies with minimal glucagon interference, mazdutide is preferred. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el Survodutide del Tirzepatide?<\/h3>\n<p>Ambos son agonistas duales de incretinas, pero activan receptores secundarios diferentes. El Tirzepatide es GLP-1 + GIP (~24% efecto en peso corporal en SURMOUNT-1). El Survodutide es GLP-1 + glucag\u00f3n (~19% en Fase 2). Las dos combinaciones de receptores producen perfiles metab\u00f3licos cualitativamente diferentes: el GIP a\u00f1ade lip\u00f3lisis en adipocitos en condiciones de ayuno; el glucag\u00f3n a\u00f1ade un gasto energ\u00e9tico sustancial y movilizaci\u00f3n de l\u00edpidos hep\u00e1ticos. El Survodutide tiene la se\u00f1al \u00fanica de fibrosis MASH debido a su efecto hep\u00e1tico impulsado por el glucag\u00f3n. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el Survodutide del Retatrutide?<\/h3>\n<p>Retatrutide adds GIP receptor activation on top of GLP-1 + glucagon \u2014 it is a triple agonist. Survodutide stops at the dual combination. Retatrutide&#8217;s Phase 2 body-weight effect (~24%) is larger than survodutide&#8217;s (~19%), suggesting GIP adds substantial benefit. Survodutide has the stronger MASH signal in its respective Phase 2 trial. For studies isolating the dual GLP-1 + glucagon combination without the GIP confound, survodutide (and mazdutide) are the cleaner tools. <\/p>\n<h3>What is the typical Survodutide dose?<\/h3>\n<p>Published Phase 2 clinical protocols use weekly subcutaneous dosing with a long titration schedule starting at 0.3\u00a0mg and stepping through 0.9, 1.8, 2.4, 3.6 to a maintenance dose of 4.8\u00a0mg weekly over approximately 24 weeks. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.9\u00a0mL equals a 4.8\u00a0mg clinical-equivalent dose. <\/p>\n<h3>\u00bfEst\u00e1 aprobado el Survodutide por la FDA?<\/h3>\n<p>No. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 3 trials for obesity and MASH are ongoing as of current literature. <\/p>\n<h3>\u00bfC\u00f3mo debe almacenarse el Survodutide?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteja de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo el Survodutide?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el liofilizado), agite suavemente y deje reposar entre 5 y 10 minutos para una disoluci\u00f3n completa (los p\u00e9ptidos acilados se disuelven m\u00e1s lentamente que los p\u00e9ptidos no modificados m\u00e1s peque\u00f1os). No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 5 mg + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries Survodutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Why is Survodutide particularly relevant for MASH studies?<\/h3>\n<p>Survodutide&#8217;s glucagon-favoured dual-receptor balance produces especially strong hepatic effects in published studies. Hepatocytes are highly enriched for glucagon receptors, so glucagon-pathway activation directly drives fatty-acid oxidation and triglyceride export from steatotic liver. Combined with the GLP-1 arm&#8217;s indirect benefits via reduced insulin resistance, the dual effect on the liver translates into the striking MASH-fibrosis-stage improvement reported in the Phase 2 trial \u2014 an outcome that distinguished survodutide from other dual and triple agonists at comparable body-weight effects. <\/p>\n<h3>\u00bfEl componente de glucag\u00f3n causa hiperglucemia?<\/h3>\n<p>La cl\u00e1sica \u201cparadoja del glucag\u00f3n\u201d se aplica a survodutide como a otros co-agonistas duales GLP-1\/glucag\u00f3n: el glucag\u00f3n por s\u00ed solo aumenta la glucosa al estimular la producci\u00f3n hep\u00e1tica de glucosa, pero la acci\u00f3n dominante reductora de glucosa del componente GLP-1 sobre la insulina y la supresi\u00f3n del glucag\u00f3n en las c\u00e9lulas beta y alfa anula este efecto. La proporci\u00f3n de equilibrio de receptores dise\u00f1ada en Survodutide logra una reducci\u00f3n neta de la glucosa a pesar de la activaci\u00f3n del receptor de glucag\u00f3n. Los datos publicados de la Fase 2 confirman una mejora en el control gluc\u00e9mico en cohortes de DM2 con la dosis de mantenimiento. <\/p>\n<h3>Does Survodutide cause side reported effects?<\/h3>\n<p>El hallazgo m\u00e1s consistente es gastrointestinal, similar a otros p\u00e9ptidos del eje GLP-1: n\u00e1useas, supresi\u00f3n transitoria del apetito y retraso en el vaciado g\u00e1strico son dependientes de la dosis y tienden a atenuarse con el largo esquema de titulaci\u00f3n utilizado en la Fase 2. Los hallazgos relacionados con el componente de glucag\u00f3n incluyen elevaciones modestas en la frecuencia card\u00edaca en reposo y (raramente) efectos transitorios en la presi\u00f3n arterial. La larga titulaci\u00f3n est\u00e1 dise\u00f1ada en parte para minimizar estos efectos. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media de Survodutide?<\/h3>\n<p>In preclinical and clinical studies, survodutide has a plasma half-life of approximately 6 days following subcutaneous administration, comparable to tirzepatide (~5 days) and slightly shorter than semaglutide (~7 days). The half-life is achieved by reversible binding to circulating serum albumin via the fatty-acid acyl tether at a lysine residue. <\/p>\n<h3>How long does Survodutide take to show effects in preclinical studies?<\/h3>\n<p>Los efectos farmacodin\u00e1micos agudos sobre la tolerancia a la glucosa y el vaciado g\u00e1strico son detectables horas despu\u00e9s de la primera dosis. Los efectos sobre el peso corporal en modelos de roedores con obesidad inducida por dieta (DIO) suelen ser estad\u00edsticamente significativos despu\u00e9s de 1-2 semanas de dosificaci\u00f3n semanal. Los efectos en MASLD\/MASH sobre el contenido de triglic\u00e9ridos hep\u00e1ticos y la normalizaci\u00f3n de ALT\/AST se acumulan durante 8-16 semanas de dosificaci\u00f3n regular. El efecto m\u00e1ximo en la composici\u00f3n corporal se desarrolla en 24-46 semanas, reflejando la trayectoria de la Fase 2. <\/p>\n<h3>\u00bfPuedo pedir Survodutide para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda Survodutide a todo el mundo desde nuestra red de env\u00edo dedicada a p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente para p\u00e9ptidos. Todos los pedidos se env\u00edan en embalajes con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, MASH, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/mazdutide\/\"><strong>Mazdutida<\/strong><\/a> \u2014 Co-agonista dual GLP-1\/glucag\u00f3n hermano \u2014 proporci\u00f3n alternativa de equilibrio de receptores<\/li>\n<li><a href=\"\/es\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Agonista triple GLP-1\/GIP\/glucag\u00f3n \u2014 a\u00f1ade GIP al perfil dual GLP-1\/glucag\u00f3n<\/li>\n<li><a href=\"\/es\/tirzepatide\/\"><strong>Tirzepatida<\/strong><\/a> \u2014 Agonista dual GLP-1\/GIP \u2014 alternativa de agonista dual que utiliza GIP en lugar de glucag\u00f3n<\/li>\n<li><a href=\"\/es\/semaglutide\/\"><strong>Semaglutida<\/strong><\/a> \u2014 Agonista simple de GLP-1 \u2014 comparador de referencia can\u00f3nico<\/li>\n<li><a href=\"\/es\/cagrilintide\/\"><strong>Cagrilintida<\/strong><\/a> \u2014 An\u00e1logo de amilina \u2014 enfoque alternativo de farmacolog\u00eda combinada<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explora el panorama de los coagonistas duales GLP-1\/glucag\u00f3n<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos multiagonistas relacionados incluyendo <a href=\"https:\/\/medsbase.com\/es\/mazdutide\/\">Mazdutida<\/a> (an\u00e1logo dual GLP-1\/glucag\u00f3n), <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (triple agonista), y <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> (dual GLP-1\/GIP). Gu\u00eda comparativa: <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide \u2014 triple agonista vs dual agonista<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Doble agonista de receptores GLP-1 + glucag\u00f3n<br \/>\n\u2705 P\u00e9ptido compacto de 29-aa de Boehringer\/Zealand (BI 456906)<br \/>\n\u2705 Fuerte se\u00f1al en fibrosis hep\u00e1tica MASH en Fase 2<br \/>\n\u2705 Balance de receptores con preferencia por glucag\u00f3n<br \/>\n\u2705 Dosificaci\u00f3n semanal (~6 d\u00edas de vida media)<\/p>\n<p><strong>Survodutida<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70984,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,6286],"class_list":["post-70759","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-survodutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70984"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70759"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70759"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70759"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}